基于AI的乳腺X线与数字断层合成筛查分诊与决策支持:配对非劣效试验
这项前瞻性配对非劣效临床试验纳入31301名接受常规乳腺X线摄影的女性,平行比较标准双盲阅读与部分自主AI支持筛查(AI判为低风险者直接判为正常,其余AI辅助双读)。AI策略使放射科医生工作量降低63.6%,癌症检出率提高15.2%(95%CI 6.6%–24.4%),但召回率非劣效未成立且升高14.8%(95%CI 9.0%–20.6%)。
要点
- AI策略使放射科医生阅读工作量降低63.6%。
- 癌症检出率从6.3/1000升至7.3/1000,提高15.2%(P<0.001)。
- 召回率非劣效未成立,升高14.8%(95%CI 9.0%–20.6%)。
核心结论
- 部分自动化AI工作流在乳腺癌筛查中可行,可避免人工阅读AI判为低风险的检查。
- AI策略提高癌症检出率并大幅降低工作量,但召回率非劣效未成立。
研究设计与样本
- 前瞻性、配对、非劣效临床试验,2022年3月至2024年1月纳入31301名接受常规乳腺X线摄影的女性。
- 平行应用标准双盲阅读与部分自主AI支持筛查两种策略。
主要发现
- AI策略放射科医生工作量降低63.6%。
- 癌症检出率提高15.2%(95%CI 6.6%, 24.4%),从6.3/1000升至7.3/1000,P<0.001。
- 召回率非劣效未成立,升高14.8%(95%CI 9.0%, 20.6%)。
- 数字乳腺X线摄影工作量降低62.1%,数字乳腺断层合成降低65.5%。
- 数字乳腺X线摄影癌症检出率增加1.6/1000、召回率增加1.3%,数字乳腺断层合成两者均稳定。
临床怎么用
- 可考虑将AI判为低风险的检查直接判为正常,以减少放射科医生阅读量。
- 应用AI策略需关注召回率升高,结合筛查模态评估获益与负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Artificial intelligence (AI) systems have been demonstrated to improve the accuracy of screening mammograms. Here this prospective, paired, noninferiority clinical trial evaluated whether AI could safely reduce workload by excluding low-risk exams from radiologist reading. Between March 2022 and January 2024, 31,301 women were included in the trial and underwent routine mammograms. Two reading strategies were applied in parallel: standard double-blind reading and partially autonomous AI-supported screening, where cases classified by AI as low risk were assessed as normal and the rest were double read with AI support. The primary outcomes were radiologist workload, cancer detection rate and recall rate. In the AI strategy, radiologist workload was 63.6% lower; the cancer detection rate was 15.2% higher (95% confidence interval 6.6%, 24.4%), increasing from 6.3 of 1,000 to 7.3 of 1,000, P < 0.001; and the recall rate was not noninferior and was 14.8% higher (95% confidence interval 9.0%, 20.6%). Subanalyses by modality highlighted a similar workload reduction in digital mammography (-62.1%) and digital breast tomosynthesis (-65.5%). However, in digital mammography, the cancer detection rate increased by 1.6 of 1,000 and the recall rate by 1.3%, while both remained stable in digital breast tomosynthesis. These results demonstrate the feasibility of a partially automated AI workflow in breast cancer screening, avoiding human reading of studies classified as low risk. ClinicalTrials.gov: NCT04849776 .
引用
- Elías-Cabot E, Romero-Martín S, Raya-Povedano JL, et al. AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial. Nat Med. 2026. PMID: 41857202. doi:10.1038/s41591-026-04277-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。